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Abstract
 
The susceptibility to infections induced by Gram-negative bacteria is largely determined by in-
nate immune responses to bacteria cell wall lipopolysaccharide (LPS). The stimulation of B cells
by LPS enhances their antigen-presenting capacity and is accompanied by B cell proliferation
and secretion of large quantities of LPS-neutralizing antibodies. Similar to macrophages and
neutrophils, the LPS-induced activation of B cells is dependent on Toll-like receptor (TLR)4.
Here, we demonstrate that the responses of B cells to LPS are also regulated by another TLR
protein, RP105, which is predominantly expressed on mature B cells in mice and humans. The
analysis of mice homozygous for the null mutation in the RP105 gene revealed impaired pro-
liferative and humoral immune responses of RP105-deficient B cells to LPS. Using originally
LPS-unresponsive Ba/F3 cells expressing exogenous TLR4 and RP105, we demonstrate the
functional cooperation between TLR4 and RP105 in LPS-induced nuclear factor 
 
k
 
B activa-
tion. These data suggest the existence of the TLR4–RP105 signaling module in the LPS-induced
B cell activation.
Key words: gene targeting • lymphocyte • activation • leucine-rich repeat • cell surface 
molecule
 
Introduction
 
A large body of evidence supports the important role of B
cells in host responses against Gram-negative bacteria.
These responses are largely triggered by bacteria cell wall
LPS. Stimulation of B cells by LPS enhances their antigen-
presenting capacity and is accompanied by B cell prolifera-
tion and secretion of large quantities of LPS-neutralizing
Abs (1, 2). In turn, LPS-neutralizing Abs are important for
clearing LPS and Gram-negative bacteria out of the circu-
lation (3). The responses of B cells to LPS are mediated by
cell surface Toll-like receptor (TLR)
 
1
 
 4, which belongs to
the multimember family of mammalian proteins homolo-
gous to Toll protein of 
 
Drosophila melanogaster
 
 (4, 5). The
TLR proteins possess an extracellular leucine-rich repeat
(LRR) domain, a single transmembrane domain, and a cy-
toplasmic domain homologous to the cytoplasmic portion
of the IL-1 receptor (5). The significance of TLR4 in B
cell activation by LPS was underscored by profoundly re-
duced in vitro and in vivo LPS responses of B cells harbor-
ing spontaneous or genetically engineered null mutations in
the TLR4 gene (6–8). The LPS signaling via TLR4 is de-
pendent on association of the LRR domain of TLR4 with
the MD-2 protein produced by TLR4-expressing cells (9).
The essential role of TLR4 in B cell responses to LPS is
contrasted by the relatively low expression levels of the
TLR4–MD-2 complex on the surface of ex vivo–isolated
mature B cells compared with peritoneal macrophages. Us-
ing the MTS510 mAb that in flow cytometry analyses rec-
ognizes TLR4 in association with MD-2 but not TLR4
alone, we found the expression levels of TLR4–MD-2 on
B cells to be 
 
.
 
10 times lower than on the peritoneal
thioglycollate–elicited macrophages (10). The hardly de-
tectable expression of TLR4–MD-2 on B cells suggests the
possible cooperation between TLR4 and other TLR pro-
tein(s) in B cell signaling of LPS. In addition to TLR4, B
cells express another member of the TLR family, the
RP105 protein (11–13). In contrast to TLR4, which is ex-
pressed on immune cells of different types, the expression
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Abbreviations used in this paper:
 
 CG, chicken 
 
g
 
-globulin; ES, embry-
onic stem; LRR, leucine-rich repeat; neo
 
r
 
, neomycin resistance; NF, nu-
clear factor; TLR, Toll-like receptor. 
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of RP105 is largely restricted to mature peripheral B cells
(11). RP105 is associated with the MD-2 homologous pro-
tein MD-1 (14, 15). Robust B cell proliferation and upreg-
ulation of the cell surface–expressed MHC class II and
costimulatory proteins B7.1 and B7.2 induced by Ab-
mediated cross-linking of RP105 revealed this TLR as a
potent regulator of B cell activation (11, 16). To test
whether RP105 controls B cell responses to LPS, as well as
to address the possible role of RP105 in B cell develop-
ment and activation, we have generated mice homozygous
for the null mutation of the RP105
 
 
 
gene. Using mice defi-
cient for RP105, we revealed an important role of RP105
in B cell activation by LPS in vitro and in vivo.
 
Materials and Methods
 
Generation of the RP105-deficient Mice.
 
The DNA clone con-
taining the RP105 gene was obtained from Genome Systems,
Inc., and the RP105 gene was subcloned into the pBluescript
vector (Stratagene). For the construction of the RP105 gene-tar-
geting vector, the 2.4-kB fragment of the exon 3 of the RP105
gene was replaced by the neomycin resistance (neo
 
r
 
) gene under
the control of the mouse phosphoglycerate kinase (PGK)-1 gene
promoter. The HSV thymidine kinase gene driven by the PGK-1
promoter was introduced at the 3
 
9
 
 end of the targeting vector.
The linearized DNA of the targeting vector was transfected into
the E14.1 embryonic stem (ES) cells, followed by selection of the
G418- and gancyclovir-resistant ES cell clones as described previ-
ously (17). The clones of double-resistant cells were collected and
genotyped by Southern blot analysis using the probe located out-
side the targeting construct. Cells of three independent recombi-
nant ES clones were used to produce chimeric mice, followed by
the generation of heterozygous RP105
 
1
 
/
 
2
 
 and homozygous
RP105
 
2
 
/
 
2
 
 mice. The RP105
 
1
 
/
 
2
 
 mice
 
 
 
were backcrossed four
times to C57BL/6 mice and RP105
 
2
 
/
 
2
 
 mice (F5) at 6–15 wk of
age, and were used for most of the experiments. The wild-type
littermates derived from the breeding of the RP105
 
1
 
/
 
2 
 
mice
were used as control. C3H/HeJ and C3H/HeN mice were ob-
tained from Japan SLC, Inc. Mice were maintained in the animal
facilities at Saga Medical School and Institute for Genetics.
 
Cell Staining and Flow Cytometry.
 
Single cell suspensions
were prepared from different lymphoid organs and incubated at
10
 
6
 
 cells per 20 
 
m
 
l on ice in staining buffer (PBS containing 0.5%
BSA and 0.01% NaN
 
3
 
) with optimal amounts of FITC-, PE-, or
biotin-conjugated Abs for 10 min. The following mAbs were
purchased from BD PharMingen: S7 (anti-CD43), B3B4 (anti-
CD23), and Ly1 (anti-CD5). The following Abs were prepared:
RA3-6B2 (anti-B220), R33-24.12 (anti-IgM), 1.3-5 (anti-IgD),
and Cfo-1 (anti-Thy1.2). Flow cytometric analysis was per-
formed on a FACScan™ cytometer (Becton Dickinson).
 
Analysis of B Cell Proliferation In Vitro.
 
Splenic B cells were
purified by negative selection with the anti-CD43 mAb S7 con-
jugated either to Dynabeads M-450 sheep anti–rat IgG (Dynal) or
to CD43-coupled magnetic beads (Miltenyi Biotec) as described
(18). B cell purity has been always 
 
.
 
95%, as judged by flow cy-
tometry analyses (data not shown). The wild-type and mutant B
cells were incubated at 2 
 
3
 
 10
 
5
 
 per well in 96-well flat-bottomed
plates with goat anti–mouse IgM F(ab
 
9
 
)
 
2
 
 (Organon Teknika) in
the presence or absence of recombinant mouse IL-4 (R&D Sys-
tems) or of rat anti–mouse CD40 mAb (LB429S; a gift from Dr.
Nobuo Sakaguchi, Kumamoto University School of Medicine,
 
Kumamoto, Japan). For the analysis of LPS responses, B cells
were treated with LPS derived from 
 
Escherichia coli
 
 0111:B4
(Sigma-Aldrich), 
 
E. coli
 
 055:B5 (Sigma-Aldrich), or 
 
Salmonella
minnesota
 
 Re595 (Sigma-Aldrich). Lipid A was either of bacterial
(
 
S. minnesota
 
) or synthetic (a gift from Dr. Teruo Kirikae, Daiichi
Pure Chemicals, Tokyo, Japan) origin.
 
Analysis of Lyn Phosphorylation.
 
Purified B cells (10
 
7
 
 per
group) were stimulated with lipid A (1 
 
m
 
g/ml) and harvested.
Cells were solubilized in lysis buffer (1% Triton X-100, 150 mM
NaCl, 50 mM Tris/HCl, pH7.5, 10 
 
m
 
g/ml soybean trypsin in-
hibitor, 1 mM PMSF, and 5 mM EDTA) supplemented with
phosphatase inhibitors (10 mM NaF and 1 mM sodium vana-
date). Lysates were applied to protein G Sepharose conjugated
with anti-Lyn mAb Lyn8 (Wako Pure Chemicals). Precipitates
(2.5 
 
3
 
 10
 
6
 
 cells per lane) were subjected to SDS-PAGE (9%
acrylamide) and electroblotting. Phosphotyrosine or Lyn was
probed with antiphosphotyrosine mAb 4G10 (Upstate Biotech-
nology) or with Lyn8, respectively. Detection was conducted
with goat anti–mouse IgG peroxidase and the SuperSignal
chemiluminescence substrate (Pierce Chemical Co.).
 
Analysis of Humoral Immune Responses.
 
The littermate con-
trol and RP105-deficient mice were immunized intraperitoneally
with 20 
 
m
 
g of TNP-LPS in PBS (three to five mice per group).
The serum concentration of TNP-specific Abs at different time
points was measured by ELISA. ELISA was performed by coating
plastic plates with TNP-BSA (10 
 
m
 
g/ml), and serial serum dilu-
tions were applied onto the plate. Bound Abs were revealed by
goat Abs specific for IgM or IgG3 isotype (Caltag Labs.).
The analyses of serum concentrations of the Abs of different
isotypes in mice immunized with T cell–independent and T
cell–dependent antigens were done as described (18). In brief,
wild-type, RP105
 
1
 
/
 
2
 
, and RP105
 
2
 
/
 
2
 
 mice were immunized
intraperitoneally with 5 
 
m
 
g of the T-independent antigen
4-hydroxy3-nitrophenylacetyl (NP)
 
25
 
-Ficoll in PBS or 50 
 
m
 
g
of the alum-precipitated T-dependent antigen NP
 
15
 
–chicken
 
g
 
-globulin (CG). The serum concentration of NP-specific Abs
was measured by ELISA.
 
Analysis of the Nuclear Factor 
 
k
 
B Activation in Ba/F3 Cells.
 
The IL-3–dependent Ba/F3 cells (19) carrying the luciferase gene
under the control of the nuclear factor (NF)-
 
k
 
B responsive ele-
ment (20) were used to study the role of TLR4 and RP105 in
the LPS-induced NF-
 
k
 
B activation. The pEF-BOS expression
vectors (21) encoding the RP105, TLR4, MD-1, or MD-2 pro-
teins of human or mouse origin were constructed as described (9,
10, 12, 14, 15). These vectors, as well as the reporter gene, were
transfected in the Ba/F3 cells as described previously (9, 10). Ba/
F3 cells expressing TLR4–MD-2, TLR4–RP105, or TLR4–
RP105–MD-1 were established by sequential transfection of
those expressing TLR4 and the reporter gene. Cell surface ex-
pression of human TLR4 and TLR4–MD-2 was shown previ-
ously (9). Expression of human RP105 and MD-1 was deter-
mined with the anti-RP105 mAb or the Ab against FLAG
epitope (Sigma-Aldrich) that had been attached at the COOH
terminus of MD-1, respectively. The expression levels of mouse
RP105–MD-1 and TLR4–MD-2 were determined by FACS
 
®
 
using the mAbs RP404 and MTS510, which recognize RP105–
MD-1 and TLR–MD2 complexes, respectively, but not RP105
or TLR4 alone (10; our unpublished results). Expression of
mouse TLR4 alone was determined by immunoblot analysis with
the Abs to the FLAG epitope that had been attached at the
COOH terminus of TLR4 (10). Transfected Ba/F3 cells were
treated with lipid A at various concentrations for 4 h. The lu-
ciferase activity was measured in cell lysates as described (9). 
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Results and Discussion
 
To test whether RP105 controls B cell responses to LPS,
as well as to address the possible role of RP105 in B cell
development and activation, we have generated mice ho-
mozygous for the null mutation of the RP105
 
 
 
gene. The
exon 3 of the RP105 gene, encoding 575 of 661 amino
acid residues of RP105 protein, was replaced by the neo
 
r
 
gene in E14.1 ES cells, which were used to generate
R105
 
2
 
/
 
2
 
 
 
mice (Fig. 1, a and b). The targeted modification
of the RP105 gene eliminates the region encoding most of
the extracellular LRR domain, the transmembrane, and
cytoplasmic domains. As expected, B cells derived from
RP105
 
2
 
/
 
2
 
 mice do not express RP105 on the cell surface
(Fig. 1 c), and because of the replacement of almost an en-
tire RP105 gene by neo
 
r
 
 are unlikely to express potentially
functional truncated RP105 protein.
The flow cytometric analyses and absolute numbers of
the bone marrow cells, splenocytes, lymph nodes, and peri-
toneal cells derived from RP105-deficient mice did not re-
veal changes in sizes of developing and mature B cell sub-
populations compared with the control wild-type mice
(Fig. 2; Table I). These data exclude the significant role of
RP105 in B cell development.
The responsiveness of RP105-deficient B cells to LPS
was tested in vitro. Using the MTS510 mAb that recog-
nizes TLR4 in association with MD-2, but not TLR4
alone, we found the expression levels of TLR4–MD2 on
wild-type and RP105-defcient cells to be 
 
.
 
10 times lower
than on the surface of peritoneal thioglycollate–elicited
macrophages (10). Furthermore, incubation of the wild-
type and RP105-defcient B cells with LPS, anti-IgM, or
anti-CD40 Abs did not upregulate surface expression of
TLR4–MD-2 (data not shown). Incubation of the purified
splenic RP105-deficient B cells with different amounts of
Figure 1. Targeted disruption of the murine RP105 gene by homolo-
gous recombination. (a) Schematic representation of the RP105 protein,
RP105 genomic locus, targeting construct, and targeted RP105 locus.
Positions of RP105 exons are shown as boxes. The indicated external
probe recognizes 4.5 Kb and 3 Kb of the PstI-digested DNA of the wild-
type and targeted RP105 genes, respectively. (b) Southern blot analysis of
the RP105 mutation in mice. The tail DNA isolated from the wild-type
C57BL/6, RP1051/2, and RP1052/2 mice was digested with Pst1 and
analyzed using the probe described above. Arrows indicate the position of
the DNA fragments corresponding to the wild-type (4.5 Kb) or targeted
(3 Kb) RP105 alleles. (c) Flow cytometry staining of RP105 was con-
ducted as described in Materials and Methods. Spleen cells from the wild-
type C57BL/6, RP1051/2, and RP1052/2 mice were stained with an
anti-RP105 mAb (RP/14) followed by goat anti–rat IgG-FITC.
Figure 2. B lymphocyte populations in RP105-deficient mice. Flow
cytometric analysis of bone marrow cells, splenocytes, thymocytes, and
peritoneal cavity cells in 8-wk-old wild-type C57BL/6 and RP105-defi-
cient mice. Numbers indicate the fraction (%) of gated cellular subpopula-
tions within the lymphocyte population. 
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LPS derived from three different bacteria strains (
 
E. coli
 
0111: B4, 
 
E. coli
 
 055: B5, and 
 
S. minnesota
 
 Re595) as well
as with synthetic lipid A results in B cell proliferation at
levels significantly lower than of LPS-triggered wild-type
control B cells (Fig. 3 a). However, RP105-deficient B
cells were not as impaired as TLR4-mutated C3H/HeJ B
cells, which did not respond to LPS or lipid A (Fig. 3 a).
Reduced proliferative response of RP105-deficient B cells
was due to the reduced number of cells entering the cell
cycle within the first 24 h after the stimulation with LPS,
and could not be overcome by costimulation of B cells
with IL-4 (data not shown). In contrast to impaired prolif-
eration in response to LPS, the proliferative responses of
RP105-deficient B cells and control wild-type B cells to
the Abs to IgM, CD40, or CD38 and IL-4 were similar
(Fig. 3 b; data not shown). These data indicate the specific
role of RP105 in B cell responses to LPS.
Lyn-deficient B cells are impaired in LPS-induced B cell
proliferation, demonstrating an important role of Lyn in
B cell signaling of LPS (22, 23). Our earlier studies re-
vealed the involvement of the Lyn–Btk–protein kinase C 
 
b
 
signaling chain in B cell activation by RP105 (16). It seems
possible that RP105 has a role in LPS-induced tyrosine
phosphorylation of Lyn. We examined tyrosine phosphor-
ylation of Lyn after LPS stimulation in wild-type and
RP105-deficient B cells (Fig. 3 c). A slight but appreciable
increase in phosphorylation was observed 1 h after LPS ad-
dition in wild-type B cells (Fig. 3 c, lanes 1–3), whereas
LPS-induced Lyn phosphorylation appeared to be weaker
in RP105-deficient B cells (Fig. 3 c, lanes 4–6).
 
Table I.
 
Absolute Numbers of B Lineage Cells in
Lymphoid Organs
 
RP105
 
1
 
/
 
1
 
RP105
 
2
 
/
 
2
 
Exp. 1 Exp. 2 Exp. 1 Exp. 2
 
(
 
3
 
10
 
2
 
6
 
)(
 
3
 
10
 
2
 
6
 
)(
 
3
 
10
 
2
 
6
 
)(
 
3
 
10
 
2
 
6
 
)
 
Bone marrow
 
*
 
Pro-B 0.26 0.4 0.3 0.4
Pre-B 0.78 1.2 0.9 2.0
Immature B 0.58 0.8 0.6 1.0
Recirculating B 0.25 0.5 0.45 0.3
Spleen
B 21.0 14.0 40.0 22.0
T 9.0 8.6 23.0 17.0
Lymph nodes
 
‡
 
B 1.6 ND 2.8 ND
T 9.0 ND 10.0 ND
Peritoneal cavity
CD5
 
1
 
IgM
 
1 
 
B 1.9 2.1 0.6 0.5
CD5
 
2
 
IgM
 
2 
 
B 0.8 0.7 0.4 0.3
Cells of lymphoid organs were counted, and absolute numbers of
lymphoid cells were calculated from the percentage of each cell
population. ND, not done; Exp., experiment.
 
*
 
From one tibia and one femur.
 
‡
 
From two inguinal lymph nodes.
Figure 3. B cell activation in vitro. (a) Pu-
rified cells were stimulated with LPS from E.
coli 0111:B4, E. coli 055:B5, S. minnesota
Re595, and synthetic lipid A. After 3 d, cells
were pulsed with 1 mCi/well  3H-TdR and
harvested, and [3H]thymidine incorporation
was counted as described (reference 9). Re-
sults were shown as mean values of cpm from
triplicate wells with standard errors. (b) Top:
purified B cells were stimulated with the fol-
lowing stimuli: the goat anti–mouse IgM
F(ab9)2 Ab (5 mg/ml), the mAb to CD40 (5
mg/ml), and recombinant mouse IL-4 (5 ng/
ml). After 3 d, cells were pulsed with 1 mCi/
well  3H-TdR, and B cell proliferation was
measured as described above. (b) Bottom: pu-
rified B cells were stimulated with goat anti–
mouse IgM F(ab9)2 Abs at various concentrations with or without IL-4, and proliferation was mea-
sured as described above. (c) Purified B cells were stimulated with lipid A (1 mg/ml) for 1 h (lanes 2
and 5) or 3 h (lanes 3 and 6). Cell lysates were immunoprecipitated with anti-Lyn mAb, and equally
divided precipitates were subjected to SDS-PAGE (9% acrylamide) and electroblotting. Phosphoty-
rosine (top) or Lyn (bottom) was probed with antiphosphotyrosine or anti-Lyn mAb, respectively.
Similar results were obtained from two independent experiments.27 Ogata et al.
The positive role of RP105 in B cell activation by LPS
was further confirmed by the analysis of humoral im-
mune responses in RP105-deficient mice immunized with
TNP-LPS. The titers of TNP-specific IgM and IgG3 were
significantly lower in the sera of the immunized RP105-
deficient mice compared with control mice (Fig. 4 a).
However, immunization with T cell–independent antigen
NP-Ficoll and T cell–dependent antigen NP-CG resulted
in equally strong immune responses in both wild-type and
RP105-deficient mice (Fig. 4, b and c). Furthermore, simi-
lar titers of serum immunoglobulins of different isotypes in
RP105-deficient and wild-type control mice (data not
shown) suggest unaltered humoral responses of RP105-
deficient B cells to environmental antigens present in the
conventional animal facility.
The involvement of RP105 in LPS signaling suggests the
possible function of RP105 either as a TLR4-independent
LPS receptor or as a coreceptor of TLR4. Considering un-
responsiveness in C3H/HeJ mice (Fig. 3 a), RP105–MD-1
cannot substitute for the lack of TLR4. We showed previ-
ously that association of MD-2 greatly enhances LPS sig-
naling via TLR4 (9, 10). However, the TLR4–MD-2
complex is hardly detectable on the B cell surface with the
MTS510 mAb that specifically reacts with the TLR4–MD-2
complex (10). Moreover, the MTS510 mAb has little effect
on LPS-dependent proliferation of B cells (our unpub-
lished results). B cells may employ another molecule to
regulate LPS signaling via TLR4. We hypothesized that the
RP105–MD-1 complex, instead of MD-2, helps TLR4 to
recognize and signal LPS in B cells. The functional cooper-
ation between TLR4 and RP105 was tested in murine Ba/
F3 cells that express neither TLR4 nor RP105 and do not
respond to LPS (9). The Ba/F3 cells carrying the stably in-
tegrated exogenous TLR4, RP105, MD-1, or MD-2 genes
alone or in different combinations were used. The expres-
sion levels of TLR4 or RP105 in the presence or absence
of coexpressed RP105–MD-1 or TLR4, respectively, were
similar as judged by immunoprecipitation or cell surface
staining with the corresponding Abs (10; data not shown).
The LPS-induced activation of NF-kB in these cells was
tested by the analysis of the NF-kB–induced upregulation
of the luciferase gene activity controlled by the NF-kB re-
sponsive element (20). The Ba/F3 cells expressing RP105–
MD-1 did not respond to LPS derived from S. minnesota
Re595 or lipid A (Fig. 5 a; data not shown). On the other
hand, Ba/F3 cells expressing mouse TLR4 alone respond
to LPS, albeit at levels significantly reduced compared with
Ba/F3 cells expressing TLR4 and MD-2 (Fig. 5 a; refer-
Figure 4. Ab responses to TNP-LPS, NP-Ficoll,
and NP-CG in RP105-deficient mice. (a) Littermate
control and RP105-deficient mice were immunized
intraperitoneally with TNP-LPS (20 mg per mouse)
and bled 1 or 2 wk later. The titers of TNP-specific
IgM or IgG3 were measured. (b) NP-specific Abs in
sera of wild-type (h), RP1051/2 (e), and RP1052/2
(s) mice immunized with T-independent antigen NP-
Ficoll. The titers of NP-specific IgM, IgG3, and
l-bearing Abs were determined at days 0, 7, 14, and 33
after immunization. (c) NP-specific Abs in sera of
wild-type (h), RP1051/2 ( e), and RP1052/2 ( s)
mice immunized with T-dependent antigen NP-CG.
The titers of NP-specific IgM, IgG1, and l-bearing
Abs were determined at days 0, 7, 14, 21, and 28 after
immunization.28 Low LPS Responsiveness in B Cells Lacking RP105
ence 10). The RP105 influence on the LPS signaling via
TLR4 was addressed by expression of RP105 with or
without MD-1 and TLR4 in Ba/F3 cells. The LPS signal-
ing via TLR4 alone was not affected by expression of
RP105 alone, whereas it was significantly enhanced in the
presence of RP105–MD-1 (Fig. 5 a). We also examined
Ba/F3 cells expressing both TLR4–MD-2 and RP105–
MD-1, the LPS responses of which were not different from
Ba/F3 cells expressing TLR4–MD-2 (Fig. 5 b).
Roles of human RP105–MD-1 in the LPS signaling via
human TLR4 were next addressed. Similar experiments
were conducted with Ba/F3 cells expressing human TLR4
and RP105. The surface expression levels of TLR4 or
RP105 in the presence or absence of coexpressed RP105–
MD-1 or TLR-4, respectively, were similar (9; data not
shown). In contrast to the Ba/F3 cells expressing murine
TLR4, the Ba/F3 cells that express human TLR4 alone do
not respond to lipid A (Fig. 5 c; reference 9). The reason
for the observed species-specific differences in LPS signal-
ing via murine and human TLR4 alone is unknown. Co-
expression of RP105–MD-1 conferred LPS responsiveness
less efficiently than that of MD-2 (Fig. 5 c). Treatment of
Ba/F3 cells coexpressing human TLR4 and RP105–MD-1
with the mAb directed against human RP105 inhibited
LPS-induced NF-kB activation as effectively as with anti-
TLR4 mAb alone (Fig. 5 d). Treatment of Ba/F3 cells
coexpressing human TLR4 and RP105–MD-1 with a com-
bination of the anti-RP105 and anti-TLR4 mAbs did not
result in further decrease in LPS-induced NF-kB activation
(Fig. 5 d), thus supporting the cooperative rather than inde-
pendent signaling capacities of TLR4 and RP105–MD-1.
RP105–MD-1 is thus able to enhance LPS signaling via
TLR4 as MD-2 does. Either MD-2 or RP105–MD-1 is
required for LPS recognition and signaling by TLR4.
However, the TLR4–MD-2 complex is hardly detectable
on the mouse B cell surface (10), where RP105–MD-1 is
abundantly expressed. Taken together with the results with
Ba/F3 transfectants, we would like to conclude that the
RP105–MD-1 complex, rather than MD-2, regulates LPS
signaling via TLR4 on the B cell surface. The structural ba-
sis for the RP105–MD-1 and TLR4 cooperation remains
unclear. Immunoprecipitation of TLR4 or RP105 from ly-
sates of splenic B cells or Ba/F3 cells coexpressing RP105–
MD-1 and TLR4 has not resulted in coprecipitation of
TLR4 or RP105, respectively (data not shown). Immuno-
precipitation in the presence of LPS did not make any dif-
ference.
Finally, the important role of RP105 in B cell activation
by LPS makes it a possible target for pharmacological inter-
vention aimed at enhancement of humoral immune re-
sponse against Gram-negative bacteria.
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